SCHEMBL5714903

SCHEMBL5714903

Cc1ccc(CCN2CCN(C(=O)Oc3ccc(Cc4ccc(C(F)(F)F)cn4)cc3)CC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 12/20 0.47
BCHE P06276 1/20 0.46
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TRPV1 Q8NER1 2/20 0.41
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
TRPA1 O75762 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714768 0.95 LIPE (0.46) LIPEBCHEHPGDSMN1; SMN2TRPV1
SCHEMBL5714345 0.95 TRPV1 (0.44) LIPEBCHEHPGDSMN1; SMN2TRPV1
SCHEMBL5714944 0.92 CYP1A2 (0.43)
SCHEMBL5715170 0.89 TRPV1 (0.43) LIPEBCHEHPGDSMN1; SMN2TRPV1
SCHEMBL5714859 0.89 LIPE (0.63) LIPEBCHESMN1; SMN2
SCHEMBL5714135 0.89 TP53 (0.49) LIPEBCHETRPV1TRPA1
SCHEMBL5715337 0.88 LIPE (0.44) LIPEBCHEHPGDSMN1; SMN2TRPV1
SCHEMBL5715403 0.88 LIPE (0.46) LIPEBCHEHPGDSMN1; SMN2TRPV1
SCHEMBL5714758 0.87 LIPE (0.44) LIPEBCHEHPGDSMN1; SMN2TRPV1
SCHEMBL5715617 0.87 LIPE (0.46) LIPEBCHEHPGDSMN1; SMN2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL LIPE 1/4885BCHE 47/4885HPGD 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.